Michelle Lin, DO
Family Medicine · Las Vegas, NVNPI 1043668015
Payments from drug & device makers
Across 226 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Scynexis, Inc.$1K
- AstraZeneca$645
- Novo Nordisk$624
- Corcept Therapeutics$599
- Pfizer$520
- plus $2K from 28 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Consulting fees$2,20031%
- Food & beverage$4,91469%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 5 | $1,237 |
| Scynexis, Inc. | 3 | $1,163 |
| AstraZeneca | 24 | $645 |
| Novo Nordisk | 37 | $624 |
| Corcept Therapeutics | 18 | $599 |
| Pfizer | 28 | $520 |
| Bayer | 11 | $237 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $200 |
| Lucid Diagnostics Inc. | 7 | $199 |
| Lilly USA, LLC | 12 | $195 |
| Optinose US, Inc. | 14 | $188 |
| Dexcom, Inc. | 3 | $148 |
| Boehringer Ingelheim | 7 | $125 |
| Astellas Pharma US Inc | 4 | $108 |
| Intuitive Surgical | 1 | $106 |
| Galderma Laboratories, L.p. | 5 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $88 |
| Daiichi Sankyo Inc. | 5 | $82 |
| Amgen | 3 | $69 |
| Mannkind Corporation | 3 | $65 |
| Intra-sana Laboratories | 4 | $58 |
| Johnson & Johnson | 2 | $57 |
| Organon | 4 | $51 |
| Philips North America LLC | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Exact Sciences | 2 | $28 |
| Viiv Healthcare Company | 1 | $27 |
| Phadia US Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| AbbVie | 1 | $17 |
| Merz North America, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,319
- FARXIGA$125
- Korlym$125
- Kerendia$122
- ELIQUIS$120
- DEXCOM G6 TRANSMITTER$112
- Da Vinci Surgical System$106
How this compares
$7,114 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $48,646 |
| OzempicSemaglutide | 29 | $39,760 |
| MounjaroTirzepatide | 20 | $21,012 |
| JardianceEmpagliflozin | 13 | $13,428 |
| FarxigaDapagliflozin Propanediol | 11 | $11,112 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,368 |
| SynthroidLevothyroxine Sodium | 19 | $1,543 |
| ProgesteroneProgesterone, Micronized | 50 | $1,501 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,396 |
| Estradiol (Twice Weekly)Estradiol | 17 | $1,163 |
| Levothyroxine Sodium | 84 | $911 |
| Levetiracetam | 15 | $796 |
| Pantoprazole Sodium | 45 | $764 |
| Testosterone Cypionate | 12 | $743 |
| Gabapentin | 65 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $624 | $39,76029 claims |
| Lilly USA, LLCMounjaro | $195 | $21,01220 claims |
| Boehringer IngelheimJardiance | $125 | $13,42813 claims |
| AstraZenecaFarxiga | $645 | $11,11211 claims |
| AbbVieSynthroid, Armour Thyroid | $17 | $1,93630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.